Therapeutic Immune Tolerance Approaches for the Treatment of Allergic Disease

C. B. Smarr*, D. R. Getts, Stephen D Miller

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter


Induction of antigen-specific immune tolerance is the desired goal for the treatment of autoimmune and allergic diseases and protection of transplanted cells and tissues. In the context of allergy, specific immunotherapy (SIT) is the only treatment option that directly targets the Th2 bias underlying allergy, but requires a long period of dose escalation with soluble antigen and carries a significant risk of adverse reactions. In this chapter, we discuss the role of Th2 cells and B cells in mediating allergic reactions and explain more recent alternate methods of inducing tolerance for the treatment of allergic disease. These include the intravenous administration of apoptotic leukocytes complexed with antigen or biodegradable poly(lactide-. co-glycolide) nanoparticles encapsulating antigen [PLG(Ag)]. PLG(Ag) nanoparticles effectively inhibit Th2 responses and allergic inflammation both prophylactically and therapeutically and are being clinically developed for allergy therapy.

Original languageEnglish (US)
Title of host publicationTranslational Immunology
Subtitle of host publicationMechanisms and Pharmacologic Approaches
PublisherElsevier Inc
Number of pages26
ISBN (Print)9780128015773
StatePublished - Dec 19 2015


  • Allergy
  • Anergy
  • Immunotherapy
  • PLG nanoparticles
  • Regulatory T cells
  • Tolerance

ASJC Scopus subject areas

  • General Medicine
  • General Immunology and Microbiology


Dive into the research topics of 'Therapeutic Immune Tolerance Approaches for the Treatment of Allergic Disease'. Together they form a unique fingerprint.

Cite this